WuXi Biologics and Immune Pharmaceuticals have entered a development and manufacturing agreement for the production of bertilimumab, Immune’s first-in-class anti-eotaxin-1 monoclonal antibody. Bertilimumab is designed to block the protein eotaxin-1, which is responsible for causing inflammation in a significant number of diseases. Immune recently completed a phase 2a trial of bertilimumab in patients with moderate-to-extensive bullous pemphigoid (BP), plans to launch a pivotal study in BP in ...